ArticleJournal of Cancer2018
Early and Partial Reduction in CD4
Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting the Microbiota-Metabolism-Immunity Axis: Active Components of Traditional Chinese Medicine in Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2026Review
- Immunomodulatory Effects of Flavonoids in Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2026Review
- Mendelian randomization study explores the peripheral immunological characteristics of colorectal cancer.Discover oncology · 2025Article
- Qingjie Fuzheng Granule prevents colitis-associated colorectal cancer by inhibiting abnormal activation of NOD2/NF-Chinese herbal medicines · 2025Article
- Causal relationship between immune cell signatures and colorectal cancer: a bi-directional, two-sample mendelian randomization study.BMC cancer · 2025Article
- Article
- ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer.EMBO reports · 2024Article
- Advances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review).Oncology letters · 2024Review
- Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?World journal of gastrointestinal oncology · 2023Review
- Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer.Nature communications · 2023Article
- Mexican Colorectal Cancer Research Consortium (MEX-CCRC): Etiology, Diagnosis/Prognosis, and Innovative Therapies.International journal of molecular sciences · 2023Review
- Mitigation of DSS-Induced Colitis Potentially via Th1/Th2 Cytokine and Immunological Function Balance Induced by Phenolic-Enriched Buckwheat (Foods (Basel, Switzerland) · 2022Article
- T-Cell-Specific CerS4 Depletion Prolonged Inflammation and Enhanced Tumor Burden in the AOM/DSS-Induced CAC Model.International journal of molecular sciences · 2022Article
- A Novel Multi-Mode Thermal Therapy for Colorectal Cancer Liver Metastasis: A Pilot Study.Biomedicines · 2022Article
- Comprehensive Analysis of Immune Infiltrates of Ferroptosis-Related Long Noncoding RNA and Prediction of Colon Cancer Patient Prognoses.Journal of immunology research · 2022Article
- The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms.International journal of molecular sciences · 2021Review
- STAT6 Is Critical for the Induction of Regulatory T Cells In Vivo Controlling the Initial Steps of Colitis-Associated Cancer.International journal of molecular sciences · 2021Article
- A prognostic model for colorectal cancer based on CEA and a 48-multiplex serum biomarker panel.Scientific reports · 2021Article
- Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.Frontiers in oncology · 2021Review
- Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer.Theranostics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in women and the third in men in North America and Europe. CRC is associated with inflammatory responses in which intestinal pathology is caused by different cell populations including a T cell dysregulation that concludes in an imbalance between activated T (Tact) and regulatory T (Treg) cells. Treg cells are CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.